NCT00499694View on ClinicalTrials.gov

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

bevacizumab

10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)

DRUG

satraplatin

80 mg/m(2), Orally, Days 1-5, every 35 days

Trial Locations (2)

48201

Veterans Affairs Medical Center - Detroit, Detroit

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00499694 - Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel | Biotech Hunter | Biotech Hunter